Scott M. Coiante
2020
In 2020, Scott M. Coiante earned a total compensation of $1.9M as Chief Financial Officer at Aprea Therapeutics, a 3% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $142,450 |
|---|---|
| Option Awards | $1,345,850 |
| Salary | $370,000 |
| Total | $1,858,300 |
Coiante received $1.3M in option awards, accounting for 72% of the total pay in 2020.
Coiante also received $142.5K in non-equity incentive plan and $370K in salary.
Rankings
In 2020, Scott M. Coiante's compensation ranked 5,853rd out of 13,090 executives tracked by ExecPay. In other words, Coiante earned more than 55.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,853 out of 13,090 | 55th |
Division Manufacturing | 2,405 out of 5,621 | 57th |
Major group Chemicals And Allied Products | 960 out of 2,254 | 57th |
Industry group Drugs | 831 out of 1,954 | 58th |
Industry Pharmaceutical Preparations | 620 out of 1,459 | 58th |
Source: SEC filing on April 28, 2021.
Coiante's colleagues
We found two more compensation records of executives who worked with Scott M. Coiante at Aprea Therapeutics in 2020.
News
Aprea Therapeutics CFO John Hamill's 2023 pay jumps 62% to $908K
April 25, 2024
Aprea Therapeutics CEO Christian Schade's 2022 pay falls 58% to $1.4M
July 11, 2023
Aprea Therapeutics CEO Christian Schade's 2021 pay slips 17% to $3.2M
June 10, 2022
Aprea Therapeutics CEO Christian Schade's 2020 pay rises 6% to $3.9M
April 28, 2021
Aprea Therapeutics CEO Christian Schade's 2019 pay jumps 520% to $3.7M
April 29, 2020